Evidence map›Paper›PMID 38510243›Full record

ArticleFrontiers in immunology2024

High hypoxia status in pancreatic cancer is associated with multiple hallmarks of an immunosuppressive tumor microenvironment.

Hassan Sadozai, Animesh Acharjee, Hateem Z Kayani, Thomas Gruber, Reginald M Gorczynski, Bernard Burke

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Review
  11. Article
  12. Tumor Hypoxia: How Conventional Histology Is Reshaped in Breast Carcinoma.International journal of molecular sciences · 2025
    Review
  13. Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Hassan Sadozai *Centre for Health and Life Sciences, Coventry University, Coventry, United Kingdom.
Animesh Acharjee *Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.
Hateem Z KayaniCentre for Health and Life Sciences, Coventry University, Coventry, United Kingdom.
Thomas GruberIndependent Scholar, National Coalition of Independent Scholars, Visp, Switzerland.
Reginald M GorczynskiInstitute of Medical Sciences, University of Toronto, Toronto, ON, Canada.
Bernard BurkeCentre for Health and Life Sciences, Coventry University, Coventry, United Kingdom.
Coventry University · GBUniversity of Birmingham · GBUniversity of Toronto · CA

Funding

Medical Research Council UK HDRUK/CFC/01
6 · The paper itself

Abstract

Introduction: Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is a particularly lethal disease that is often diagnosed late and is refractory to most forms of treatment. Tumour hypoxia is a key hallmark of PDAC and is purported to contribute to multiple facets of disease progression such as treatment resistance, increased invasiveness, metabolic reprogramming, and immunosuppression. Methods: We used the Buffa gene signature as a hypoxia score to profile transcriptomics datasets from PDAC cases. We performed cell-type deconvolution and gene expression profiling approaches to compare the immunological phenotypes of cases with low and high hypoxia scores. We further supported our findings by qPCR analyses in PDAC cell lines cultured in hypoxic conditions. Results: First, we demonstrated that this hypoxia score is associated with increased tumour grade and reduced survival suggesting that this score is correlated to disease progression. Subsequently, we compared the immune phenotypes of cases with high versus low hypoxia score expression (Hypoxia Discussion: In summary, we demonstrated novel associations between hypoxia and multiple immunosuppressive mediators in PDAC, highlighting avenues for improving PDAC immunotherapy by targeting these immune molecules in combination with hypoxia-targeted drugs.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsDisease ProgressionHumansHypoxiaTumor Microenvironmentgalectinshypoxiaimmune checkpointpancreatic ductal adenocarcinoma (PDAC)tumor microenvironment (TME)

Identifiers

PMID38510243
PMCPMC10951397
OpenAlexW4392515719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.